Jordin Wilcher

Jordin Wilcher

Associate

Technology Transactions

Jordin Wilcher is an associate in Wilson Sonsini Goodrich & Rosati’s San Diego office, where she is a member of the technology transactions practice. She focuses on life sciences commercial agreements and intellectual property matters, as well as technology-related transactions such as licensing and strategic relationships.

Experience

Education

J.D., University of California, Irvine School of Law, 2021
Pro Bono Graduation Honors, American Bar Association Law Student Division Council, Delegate of Programming (2020-2021)
B.S., Biochemistry, West Virginia University, 2018Promise Scholar, Rhododendron Scholar

Admissions

State Bar of California

Credentials

Education

J.D., University of California, Irvine School of Law, 2021
Pro Bono Graduation Honors, American Bar Association Law Student Division Council, Delegate of Programming (2020-2021)
B.S., Biochemistry, West Virginia University, 2018Promise Scholar, Rhododendron Scholar

Admissions

State Bar of California

Recent Insights

Client Highlights

On October 22, 2024, AvenCell Therapeutics, a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, announced that it has raised $112 million in Series B financing. The financing was led by global life sciences investor Novo Holdings. New investors F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital, and NYBC Ventures also participated in the round alongside founding investor Blackstone Life Sciences. Wilson Sonsini Goodrich & Rosati advised Novo Holdings and F-Prime Capital on the transaction.

Learn More

Client Highlights

On May 2, 2024, Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, announced the close of a $103 million Series A financing co-led by Novo Holdings and MPM BioImpact, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures, and Palo Santo. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction.

Learn More